Answers are grounded in this paper and cite their sources.
Prospective multicenter study evaluates NASOX therapy outcomes in patients with pancreatic cancer, indicating promising anti-tumor effects.
e16446 Background: Neoadjuvant therapy has become standard practice for selected patients with pancreatic cancer, with proven benefits in improving R0 resection rates and survival outcomes; nevertheless, optimal regimen selection remains poorly defined due to a lack of high-quality evidence. This study evaluated the efficacy and safety of the NASOX regimen—liposomal irinotecan, oxaliplatin, and S-1—as neoadjuvant therapy in patients with high-risk resectable, borderline resectable (BRPC), or locally advanced pancreatic cancer (LAPC). Methods: This ongoing prospective multicenter study enrolled patients with cytologically confirmed pancreatic cancer, an ECOG performance status of 0–2, adequate organ function, and no prior anticancer therapy. Patients received 4-6 cycles of neoadjuvant NASOX (liposomal irinotecan 50 mg/m², oxaliplatin 60 mg/m 2 , S-1 40 mg/m 2 , every 2 weeks), with each cycle defined as 4 weeks and consisting of two administrations. Tumor response was assessed every 2 cycles according to RECIST v1.1, and serum CA19-9 levels were monitored biweekly. The primary endpoint was surgical conversion rate. Secondary end points included R0 resection rate, objective response rate (ORR), progression-free survival (PFS), overall survival (OS), and safety. Results: Between December 2023 and December 2025, 26 patients were enrolled (median age 58 years (range: 35–75); 34.6% females (n = 9)), including 1 (3.8%) high-risk resectable, 4 (15.4%) BRPC, and 21 (80.8%) LAPC. Among 18 patients with efficacy evaluation result, 8 achieved partial response (PR), 8 had stable disease (SD), and 2 had progressive disease (PD), yielding an ORR of 44.4% (8/18) and a DCR of 88.8% (16/18). Following multidisciplinary team (MDT) discussion, 7 patients were deemed suitable for surgical exploration; 2 declined surgery for non-medical reasons. 5 patients (25.0%) underwent resection, all achieving R0 resection. Median PFS and OS have not yet been reached. Among 16 patients completing planned therapy, median CA19-9 levels decreased from 580.9 U/mL at baseline to 213.5 U/mL; nine patients achieved > 50% reduction, and three normalized CA19-9 levels. Grade ≥3 treatment-related adverse events occurred in 38.5% of patients, most commonly neutropenia (19.2%) and vomiting (11.5%). No treatment-related deaths were observed. Conclusions: Neoadjuvant NASOX demonstrates promising antitumor activity with a manageable safety profile in patients with pancreatic cancer, supporting further prospective evaluation.
No takes yet. Share an insight, caveat, or question.
Zhou et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: